3 not yet recruiting, 2 terminated, 1 recruiting. 2 Phase 1, 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Not yet recruiting 1, Terminated 1 |
| Phase 2 | 2 | Not yet recruiting 1, Terminated 1 |
| Not applicable | 1 | Not yet recruiting 1 |
Follow Marginal Zone B Cell Lymphoma: new trials by email Literature Review of Marginal Zone B Cell Lymphoma trials Research Report on Marginal Zone B Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas CART Infusion - Lymphoma Nonhodgkin, Marginal Zone B Cell Lymphoma | Phase 2 | Not yet recruiting | Kure Cells, INC | 105 | 2026-08-31 | 2026-07-20 |
| Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors Connected home blood pressure monitoring with daily IPA supervision. - Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma ( FL) | Not applicable | Not yet recruiting | Centre Hospitalier de la côte Basque | 40 | 2026-07-01 | 2026-06-22 |
| JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma JWCAR239, Fludarabine, Cyclophosphamide - B-Cell Non-Hodgkin Lymphoma, Large B Cell Diffuse Lymphoma | Phase 1 | Not yet recruiting | Peking University Cancer Hospital & Institute | 20 | 2025-07-01 | 2025-06-17 |
| Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas Marginal Zone B Cell Lymphoma | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 160 | 2025-05-01 | 2025-02-04 | |
| Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma Umbralisib, Rituximab - Lymphoma, Follicular Lymphoma | Phase 2 | Terminated | Massachusetts General Hospital | 18 | 2019-09-01 | 2026-02-27 |
| A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma ME-401, Rituximab, Zanubrutinib - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 1 | Terminated | MEI Pharma, Inc. | 97 | 2016-10-01 | 2023-05-09 |
Lymphoma, B-Cell, Marginal Zone (6) · Lymphoma, Follicular (4) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, Mantle-Cell (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Hypertension (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Waldenstrom Macroglobulinemia (1)
Hemic and Lymphatic Diseases (6) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Lymphoproliferative Disorders (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Lymphoma (5) · Lymphoma, B-Cell (5) · Lymphoma, Non-Hodgkin (5) · Chronic Disease (2) · Disease Attributes (2) · Hematologic Diseases (2) · Leukemia (2) · Leukemia, B-Cell (2)
Rituximab (2) · Cyclophosphamide (1) · ME-401 (1) · fludarabine (1) · umbralisib (1) · zanubrutinib (1)
Centre Hospitalier de la côte Basque (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Kure Cells, INC (1) · MEI Pharma, Inc. (1) · Massachusetts General Hospital (1) · Peking University Cancer Hospital & Institute (1)
United States (2) · China (1) · Italy (1) · Switzerland (1)
Jacob D. Soumerai, MD (1) · Pier Luigi Zinzani, MD (1)